Cencora, Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 1,409 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Walgreens Boots Alliance was AmerisourceBergen/Cencora's largest and longest-running strategic shareholder, dating to a 2013 pharmaceutical distribution partnership with warrants, expanded via a 2021 Share Purchase Agreement, and progressively reduced through 2022 to 2024 via a series of Share Repurchase Agreements between the two companies and prepaid variable share forward transactions referencing WBA's Cencora shares. The last filed size was 19,980,000 shares (10.2%) as of the Schedule 13D/A Amendment No. 18 filed 20 Aug 2024. WBA's ownership fell below the 5% reporting threshold in early June 2025 when the remaining prepaid variable forwards settled (Cencora 8-K, 28 May 2025, disclosing director Ornella Barra's resignation in anticipation of this), confirmed in Cencora's 2026 proxy statement. WBA itself was taken private by Sycamore Partners on 28 Aug 2025 and split into distinct business units. No filing found discloses WBA's exact post-settlement Cencora share count; it may be zero, a small residual, or something in between, so this research leaves it null in the register per the brief rather than reporting the stale 19,980,000/10.2% figure as current.
• Walgreens (and its Boots UK affiliate) remains Cencora's largest customer relationship even without the equity stake: per the FY2025 10-K, Walgreens and Boots together accounted for approximately 25% of Cencora's fiscal 2025 revenue and about 38% of accounts receivable, net, as of 30 September 2025. The 10-year US pharmaceutical distribution agreement (US PVA) and the WBAD generics-sourcing arrangement each run through 2029; the Boots UK agreement runs through 2031.
• Holdings is empty and that is a sourced finding, not a gap. Cencora's only recent equity method investment, a 34.9% interest (originally $718.4 million, invested June 2023) in a joint venture with TPG Inc. that owned OneOncology, LLC, a private oncology-practice network, was extinguished on 2 February 2026 when Cencora acquired the majority of the outstanding equity interests it did not already own (total fair value consideration $7,387.1 million), consolidating OneOncology and recording a $1,086.6 million gain on remeasurement of the prior equity method stake. OneOncology physicians and management retained an 8% interest, but that is now a noncontrolling interest in a Cencora-consolidated subsidiary, i.e. someone else's stake in Cencora, not the reverse, and is excluded per the brief. Retina Consultants of America (RCA), acquired 2 January 2025 for an 85% interest, was consolidated from the acquisition date and is likewise excluded as a controlling stake, not a minority holding. The Q3 FY2026 10-Q (period ended 30 June 2026, filed 5 Aug 2026) and the FY2025 10-K (period ended 30 September 2025, filed 25 Nov 2025) were searched for 'equity method', 'unconsolidated', 'non-marketable', 'measurement alternative', 'joint venture', 'investment in', 'affiliate', 'noncontrolling', 'minority interest', 'Profound', 'Elevate', 'Alliance Healthcare' and 'OneOncology'. Alliance Healthcare, Innomar, World Courier, MWI Animal Health and PharmaLex are wholly owned operating businesses within the International Healthcare Solutions segment, not equity stakes in other companies, and are excluded. The only remaining trace of minority equity activity is a combined 'Cost of equity investments' cash flow line of $28.5 million for the nine months ended 30 June 2026 (versus $193.8 million in the prior-year period, which was mostly the now-superseded OneOncology-related activity); no investee is named for this balance in either filing, so per the brief this combined figure is not assigned to any single holding.
• Cencora has a September fiscal year end; the FY2025 10-K covers the year ended 30 September 2025 and the most recent 10-Q covers the quarter ended 30 June 2026 (filed 5 August 2026, cover page shows 190,827,165 shares outstanding as of 31 July 2026). Register percentages use this 190,827,165 share count as the primary denominator for the 13F rows (all dated 30 June 2026); the DEF 14A insider rows use the proxy's own 194,499,746 shares outstanding as of its 30 November 2025 record date, noted per row.
• The ticker changed from ABC to COR with the August 2023 corporate rename from AmerisourceBergen Corporation to Cencora, Inc. CUSIP 03073E105 was used as the reliable key across all 13F lookups; several filers still label the issuer 'CENCORA INC' in their information tables, none of the checked filers used the old 'AMERISOURCEBERGEN' name for the Q2 2026 period.
• THOUSANDS TRAP found and fixed: T. Rowe Price Associates, Inc.'s Q2 2026 Form 13F-HR reports its two Cencora lines' dollar values in thousands rather than whole dollars (raw value fields of $1,901,983 and $116,426 against 7,132,687 combined shares implied about $0.27/share). Rescaled x1000 to $2,018,409,000, which implies $283.02/share, consistent with every other Q2 2026 filer in this register (all cluster at $281.65 to $283.02/share).
• Vanguard case: parent Vanguard Group Inc. (CIK 0000102909) filed a 13F-NT (notice, no holdings) for the quarter ended 30 June 2026, so per the brief's Vanguard rule the two successor entities that filed 13F-HR with actual holdings, Vanguard Capital Management, LLC (CIK 0002100119) and Vanguard Portfolio Management, LLC (CIK 0002100121), are summed as one row naming both entities. This is the successor case, not an aggregate/proxy container, so is_aggregate is not set on it.
• Capital Group case checked and confirmed NOT the Vanguard successor pattern: all three Capital Group filer entities named in the brief were checked individually. Capital Research Global Investors (CIK 0001422848) held 1,979,942 Cencora shares in its own Q2 2026 Form 13F-HR. Capital World Investors (CIK 0001422849) and Capital International Investors (CIK 0001562230) had zero exposure to CUSIP 03073E105, confirmed by parsing each filer's full information table directly (no row for that CUSIP prefix at all, not just a name-fragment miss). So the Capital Group register row reflects one entity only.
• The 2026 proxy statement's own '5% and greater owners' table (record date 30 November 2025) lists only Vanguard Group Inc. (22,478,981 shares, 11.6%) and BlackRock, Inc. (16,405,771 shares, 8.4%); Walgreens is absent, corroborating that WBA had already fallen below 5% by that date. These proxy-dated figures are not used as separate register rows (they would double count the 13F-sourced Vanguard and BlackRock rows above, just at a different date); they are recorded here only as a cross-check. The proxy figures are noticeably higher than the 30 June 2026 13F figures for both, consistent with a declining share price and/or reduced positions between 30 Nov 2025 and 30 June 2026, not examined further.
• Register self-gate (computed as the chart computes it, from this file): 17 rows. Members rolling up: Robert P. Mauch (114,546) and Steven H. Collis (381,173) roll into the aggregate group container 'All directors and executive officers as a group (15 people)' (743,823 shares), which is reduced to 248,104 for the total. Walgreens contributes 0 (shares left null, not carried as stale). Total = 91,868,550 shares against 190,827,165 shares outstanding = 48.14%. This is inside the 15 to 55 percent outer band the brief allows (above the 25 to 45 percent expected range because 13 institutional 13F holders were included, more than the minimum 8 to 12), and no double counting was found: each institutional row is one filer's own 13F-HR at CUSIP 03073E105, the DEF 14A Vanguard/BlackRock figures were deliberately excluded from the sum to avoid duplicating the 13F rows, and only Mauch/Collis (not the DEF14A 5%-owner rows) roll into the insider aggregate.